RBFOX2 and neoplasm: As EMT is generally linked to tumour progression and poor clinical outcome, several studies have indicated that EMT-linked alternative splicing patterns regulated by splicing regulators including RBFOX2 may be biomarkers of aggressive tumour types, especially in lung, breast, and colon cancer [36,109].